Benchmark participates in gene editing research

RNS Number : 6250Y

Benchmark Holdings PLC

07 December 2017

 

RNS Reach

Benchmark Holdings plc

("Benchmark" or the "Company")

Benchmark participates in gene editing research to develop disease resistance in salmon

Benchmark, the aquaculture health, nutrition, and genetics business, is pleased to announce its participation in an important gene editing research project.

·    Third party funded study to investigate the potential for gene editing technology to increase resistance against infectious salmon anaemia (ISA)

·    Gene editing represents a significant long-term opportunity in animal health, following on from recent breakthroughs in human health

·    First of a number of initiatives being undertaken by Benchmark in this field for wider applications

The study, funded by a £500,000 Industrial Partnership Award from the UK's Biotechnology and Biological Sciences Research Council (BBSRC), will last three years and will investigate the possible use of gene editing technology to increase resistance against ISA. Project collaborators include individuals from the Roslin Institute, the University of Aberdeen, Benchmark's SalmoBreed, the Institute of Marine Research (Norway), INRA (France), Marine Science Scotland (Aberdeen) and Cefas (UK).

The aim of the study is to identify genes involved in the infection of Atlantic salmon by ISA and make alterations to increase resistance.  This could then be applied to produce ISA resistant broodstock for farming. 

Gene editing is a new technology which uses enzyme systems such as CRISPR/Cas9 and TALEN amongst others to make precise, targeted alterations to the DNA sequence.  In contrast with previous technologies it does not rely on introduction of genes from other species.

ISA causes high mortality and significant monetary losses in affected salmon farms worldwide, and is a major welfare issue. There are no treatments for ISA and, in the event of an outbreak, producers are forced to cull all affected stock. Existing solutions such as vaccination and biosecurity cannot fully prevent the spread of the disease. Gene editing can provide an additional way to combat ISA.

 

This study is the first of a number of initiatives being undertaken by Benchmark in this field. Gene editing represents a significant long-term opportunity, and learnings from this study will be applied to other disease areas and species including shrimp and tilapia.

 

Malcolm Pye, Benchmark CEO, commented: 

"Gene editing is a potentially powerful tool to combat disease in aquaculture and, with a team of world class geneticists, Benchmark is at the forefront of this research in line with our strategy of developing world class aquaculture health products. This is a very exciting time for gene editing with major breakthroughs in human health resulting from decades of research which augur well for animal health. We are delighted to be collaborating with leading institutions to use this novel technology to improve the health and welfare of farmed fish."

 

Enquiries

Benchmark Holdings plc                                                                  

Malcolm Pye, CEO

Ivonne Cantu, Investor Relations Director

Rachel Aninakwah, Communications

Numis                                                                                            Tel: [phone]

Michael Meade / Freddie Barnfield (NOMAD)

James Black (Corporate Broking)

MHP Communications                                                                 Tel: [phone]

Katie Hunt / Reg Hoare /Alistair de Kare-Silver                            [e-mail]

Notes to Editors:

Benchmark challenges the status quo in aquaculture.

Since 2000, Benchmark has consistently worked to build a platform to serve its customers, helping food producers take control of their biological environment through the combination of genetics, nutrition, health and knowledge services. Through its in-depth knowledge of animal biology Benchmark is able to tackle the key issues facing producers primarily in the aquaculture sector.

The Company has proven distribution capabilities in high growth markets and operates internationally with R&D facilities, commercial farms, diagnostic laboratories, manufacturing sites, production facilities and commercial offices across 27 countries in five continents. As at 30 September 2017, Benchmark employed 952 people.

For further information on Benchmark please visit www.benchmarkplc.com.

 

END

 

 

NRAKQLFBDLFBFBX